Financials data is unavailable for this security.
View more
Year on year Genmab A/S had net income fall -20.18% from 5.45bn to 4.35bn despite a 13.57% increase in revenues from 14.51bn to 16.47bn. An increase in the selling, general and administrative costs as a percentage of sales from 18.19% to 19.74% was a component in the falling net income despite rising revenues.
Gross margin | 74.05% |
---|---|
Net profit margin | 30.69% |
Operating margin | 32.00% |
Return on assets | 16.25% |
---|---|
Return on equity | 18.27% |
Return on investment | 17.48% |
More ▼
Cash flow in DKKView more
In 2023, Genmab A/S increased its cash reserves by 50.28%, or 4.97bn. The company earned 7.38bn from its operations for a Cash Flow Margin of 44.80%. In addition the company used 1.28bn on investing activities and also paid 606.00m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 498.87 |
---|---|
Tangible book value per share | 498.51 |
More ▼
Balance sheet in DKKView more
Current ratio | 12.46 |
---|---|
Quick ratio | 12.42 |
Total debt/total equity | 0.0311 |
---|---|
Total debt/total capital | 0.0301 |
More ▼
Growth rates in DKK
Growth rate information is not available.
EPS growth(5 years) | 22.71 |
---|---|
EPS (TTM) vs TTM 1 year ago | 5.08 |